Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer - Wikidata - wikimedia - TriplyDB

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

http://www.wikidata.org/entity/Q24563045

about

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide Tamoxifen Resistance: Emerging Molecular Targets MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer Triple negative breast cancer: looking for the missing link between biology and treatments The role of androgens in experimental rodent mammary carcinogenesis Targeting the androgen receptor in prostate and breast cancer: several new agents in development Androgen Receptor: A Complex Therapeutic Target for Breast Cancer Molecular Classification of Triple-Negative Breast Cancer Breast cancer molecular subtypes: from TNBC to QNBC Concepts and targets in triple-negative breast cancer: recent results and clinical implications Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women Androgen Receptor as a Potential Target for Treatment of Breast Cancer.Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.A genetic basis for the variation in the vulnerability of cancer to DNA damage.Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.Subtyping of triple-negative breast cancer: implications for therapy Coagulation factor VII is regulated by androgen receptor in breast cancer.AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.Molecular characterization and targeted therapeutic approaches in breast cancer Targeting thyroid hormone receptor beta in triple-negative breast cancer.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients Androgen receptor status is highly conserved during tumor progression of breast cancer.Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo

P2860

Q21195191-11BFB0F6-40F8-4AA4-B680-D658A0D7D7DE Q26739969-C784F63F-9B18-4614-A9DC-5899B2BDF88B Q26775086-2B4D880C-B9D5-474B-90FA-2B487DA58304 Q26783122-CC17F7E7-31A1-4669-981C-AFC4296DEC98 Q26864598-03E0A3DB-2228-476E-AA7B-0C83EBB0B023 Q27009424-D393ECE6-CDC7-4686-B854-35414B06CE32 Q28075188-C68281FC-0179-4DE4-9D21-3E34D1D2FB8A Q28076661-73ECE492-F4E7-4A4B-8B6D-20FCE46FC909 Q28076805-F91E9080-5609-49C4-A12A-9806B6F1B985 Q28078992-59CCED4C-1C7A-440B-9FEA-AF50357F9B5D Q28079858-9F11B7AC-F38B-4726-8B77-CD6F05108AF0 Q31040253-B89041C5-2061-4D17-BD89-B6555C90DAFE Q33591876-D03085E2-1833-4C47-9245-C3239B266993 Q33618290-27C749AD-381A-41D7-A11B-23A1422F65AF Q33625672-2DDE63E5-3887-4443-9BF6-C9167881E800 Q33632582-288E2964-E8E3-40C8-B209-281F2325853C Q33697429-EA02E629-8123-4117-97E9-707E9A265EC1 Q33698278-F34D1B80-0EC4-498A-ADF1-E6EDA664ACBE Q33769821-DE7D5AB3-46E2-4EFF-9E38-AFB0D8695499 Q33874621-B4FE60CE-1C70-40A3-8CED-FFA57C39ECB1 Q33887682-F1A88C1E-1ADC-42CF-99D6-47D475FABDB7 Q33913872-7750EDC9-EF4E-4B14-B8DE-B2BF2F6F73ED Q33915040-8DD387FF-C368-438F-9DAB-89BB504D1594 Q33932665-E50C2252-5C79-446B-807D-D2D99B070791 Q33966915-8EE8F5A5-E6AF-412F-B4B3-014CBD91133B Q34296476-931A87CE-88E6-4CD1-80D5-6C4039306167 Q34309894-693E8C74-4854-4C71-B1A8-83E2A7B208E6 Q34476337-4FC21144-D263-420F-9493-1E22EBCCD1EF Q34522279-06DBC4F2-B2AB-4CC0-9B7B-FEC40561B7A9 Q34523304-D4266F40-C87A-4F1E-9BD9-0DA6AEF62DED Q34547261-384FAFFF-63E0-4E7C-B99C-DE747ACF84E2 Q34550256-876970E5-BD58-4943-9460-7B9BB5E961D0 Q34734477-53BE407E-992B-417F-8E01-2993208C2339 Q34995790-F5F4BBB4-E440-419F-873A-11B0CF85C137 Q35112392-48D4E4CE-F82E-4A06-8562-85B85C4CC574 Q35530143-0406D8B3-4530-42A0-B59D-B0551E8339B6 Q35564703-92FF302F-DF28-4EAD-A4F8-E65EDFAE2371 Q35651216-8C8E45DE-F80D-4844-8C24-BDAD6F019736 Q35836387-3344504E-1960-490C-8614-EE11B0E5FD34 Q35946392-FC7BC7F0-F244-4983-A25B-BA363F5BF77F

P2860

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

http://www.wikidata.org/entity/Q24563045

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@ast

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@en

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@nl

type

label

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@ast

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@en

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@nl

prefLabel

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@ast

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@en

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@nl

P1433

Q24563045-E9ACE813-7D7E-4BA7-A4A8-453DCCD76863

P1476

Q24563045-1B334480-A61D-4056-8514-A0D4AFD2C8D7

P2093

Q24563045-10CB5BB0-EAF6-4245-89A3-A61DCC64D67C

Q24563045-383110C8-91E6-4891-80DE-9214787F56D0

Q24563045-38C2DA1E-C4FB-4685-B7B7-1FA82207D27C

Q24563045-56CEC001-7639-4A69-9D9E-5E88D41341F6

Q24563045-6592F35A-D5FD-4DAC-8FAE-F7C0C2B0EA19

Q24563045-65DC9F1D-FF57-42A0-806C-5D0C4D97116F

Q24563045-6873C754-BD9F-4C61-9641-9FDD66531B3C

Q24563045-71573EC0-ECE3-46B5-82D5-FE4F85844399

Q24563045-8C8769BB-0E03-4A4C-99F8-DE5807E5381C

Q24563045-8ED55247-812B-4597-89E6-D3CBFE3EF511

P2860

Q24563045-0031490A-7FCC-41AB-BC50-B510846AE4AB

Q24563045-02573013-05E8-4797-B68C-CD8B637BAE72

Q24563045-031F1C66-CB6E-49E3-BFEE-2963D5B42F33

Q24563045-06789B80-055C-40BB-8478-9E3A856615D9

Q24563045-1608CBD9-080C-4F5B-82A3-42205808A746

Q24563045-2FA52F8A-796E-49D6-A137-C5076971AAE3

Q24563045-3EC1FA8E-FC51-4988-8F42-6A23AABFEDD5

Q24563045-42D88F8F-93F4-4F07-8357-910D4F878DC9

Q24563045-43FACFCA-D740-43F4-A0F9-8C29F49F93C2

Q24563045-46136B33-F175-48C2-B8D0-4F7F4A59DF0D

P304

Q24563045-F9614F81-9DCD-4AD8-8BBB-E5B285AE2D5D

P31

Q24563045-8E1CEAD3-B837-40C5-8C79-7EAD83A7126F

P3181

Q24563045-F66098A3-7706-4516-B14E-7C84DA5E1330

P356

Q24563045-EAB18AEA-AEDB-49A0-BE48-735DE71CA3FC

P407

Q24563045-489B1CB4-3F16-497B-81FE-93C4F37AA39D

P433

Q24563045-1A9217CB-B8F0-4CE3-8DBE-6FB853625385

P478

Q24563045-28B30FDA-D2D0-4ECB-BE58-111E3C102B28

P50

Q24563045-64556CD0-5437-45F8-A447-BC83BA8F6F86

P577

Q24563045-80DEA153-01DE-4A55-901D-5A015D69587F

P698

Q24563045-9BC92839-0092-4727-A960-BCD8E42E1E63

P921

Q24563045-93FA313D-F449-43B9-8DD1-EF002844D100

P932

Q24563045-7469A7D4-D256-454A-8782-68242B5C4D90

P3181

P356

1078-0432.CCR-12-3327

P1433

Clinical Cancer Research

P1476

Phase II trial of bicalutamide ...... ative metastatic Breast Cancer

@en

P2093

Andres Forero

http://www.w3.org/2001/XMLSchema#string

Arooj Akhtar

http://www.w3.org/2001/XMLSchema#string

Ashley S Doane

http://www.w3.org/2001/XMLSchema#string

Ayca Gucalp

http://www.w3.org/2001/XMLSchema#string

Clifford A Hudis

http://www.w3.org/2001/XMLSchema#string

Dilip D Giri

http://www.w3.org/2001/XMLSchema#string

Hope Rugo

http://www.w3.org/2001/XMLSchema#string

James N Ingle

http://www.w3.org/2001/XMLSchema#string

Joseph M Gonzalez

http://www.w3.org/2001/XMLSchema#string

Kimberly Blackwell

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting androgen receptor in estrogen receptor-negative breast cancer

Cancer statistics, 2012

New alternative treatment in hirsutism: bicalutamide 25 mg/day

Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.

Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance.

Triple-negative breast cancer: clinical features and patterns of recurrence.

P304

5505-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1460441

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-12-3327

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23965901

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4086643

http://www.w3.org/2001/XMLSchema#string